Novo Nordisk shares remain clearly below the peaks of a few years ago, but today's session is seeing solid gains. On the wave of news from the FDA, shares of the Danish pharmaceutical company are rising by over 9%.
The direct catalyst for today's increase is the FDA (Food and Drugs Administration) decision regarding the approval of the oral version of the drug "Wegovy"
From a market perspective, the significance of this decision goes beyond the product itself.
- Firstly, approval by the American regulator reduces key regulatory risk, which in recent quarters has been one of the negative price-forming factors.
- Secondly, this decision increases the predictability of future revenues in the segment that constitutes the main source of the company's growth.
In recent quarters, investors have focused almost exclusively on risks. The most frequently pointed out included increasing competition in the GLP-1 segment, potential price and regulatory pressure from public payers in the USA, the risk of margin normalization, and concerns that the growth rate observed in recent years is not sustainable. As a result, the company's valuation underwent a drastic correction.
At the same time, the market has significantly less accounted for positive factors. The FDA decision is a good example here, as it concerns not only a new form of the drug but also a structural expansion of market share. Oral therapy lowers adoption barriers, increases acceptance among patients, and facilitates negotiations with insurers, which in the long term may translate into larger sales scale. Simultaneously, Novo Nordisk is the first company to offer such a non-invasive solution to a serious problem, giving it a significant advantage over current and future competition in the sector.
From a valuation perspective, this means that the market has already accounted for the negative scenario, while positive scenarios remain limitedly reflected in the share price. The current rebound can thus be interpreted not as a one-time reaction to information, but as the beginning of a correction of previous underestimation of potential.
If operational fundamentals remain stable and the company can effectively monetize the expansion of its product offering, the current valuation still offers significant growth potential. It is essential to closely monitor communications from US regulators and their relations with company representatives.
NOVOB.DK (D1)
Source: xStation5
BREAKING: CB consumer sentiment bellow expectations!🔥📉
BREAKING: US industry data slightly better than expected!🏭📈
BREAKING: EURUSD trades lower after US GDP Q3 report 📌
Chart of the day: GOLD (23.12.2025)
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
